Collaborative Arrangements and Licensing Agreements, Research, Development and Commercialization Partners - Janssen Biotech, Inc. (Details)	3 Months Ended								12 Months Ended
	Dec. 31, 2015 USD ($)	Sep. 30, 2015 USD ($)	Jun. 30, 2015 USD ($)	Mar. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)	Sep. 30, 2014 USD ($)	Jun. 30, 2014 USD ($)	Mar. 31, 2014 USD ($)	Dec. 31, 2015 USD ($) Drug	Dec. 31, 2014 USD ($)	Dec. 31, 2013 USD ($)
Collaborative Arrangement and Licensing Agreement [Abstract]
Revenue earned	$ 51,571,000	$ 49,121,000	$ 120,428,000	$ 62,583,000	$ 84,861,000	$ 44,063,000	$ 57,076,000	$ 28,161,000	$ 283,703,000	$ 214,161,000	$ 147,285,000
Janssen Biotech, Inc. [Member] | Agreement Entered Into in December 2014 [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Number of programs under which drugs are to be developed and commercialized | Drug									3
Cumulative payments and/or fees received	35,000,000								$ 35,000,000
Maximum amount of payments receivable	800,000,000								800,000,000
Next potential milestone	5,000,000								5,000,000
Revenue earned									8,900,000	$ 0	$ 0
Deferred revenue	26,300,000								26,300,000
Janssen Biotech, Inc. [Member] | Agreement Entered Into in December 2014 [Member] | Development Milestones [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Maximum amount of payments receivable	175,000,000								175,000,000
Janssen Biotech, Inc. [Member] | Agreement Entered Into in December 2014 [Member] | Regulatory Milestones [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Maximum amount of payments receivable	420,000,000								420,000,000
Janssen Biotech, Inc. [Member] | Agreement Entered Into in December 2014 [Member] | Commercialization Milestones [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Maximum amount of payments receivable	$ 180,000,000								$ 180,000,000